Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Genoa Pharmaceuticals logo — Pioneering a breath of hope with innovative therapies for id...

Genoa Pharmaceuticals

Pioneering a breath of hope with innovative therapies for idiopathic pulmonary fibrosis since 2011.

Founded 2011 1 employees Series A Total: $64.18M Biopharma, Biotechnology

General Information

Company Name Genoa Pharmaceuticals
Founded Year 2011
Employees 1
Industries Biopharma, Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Genoa Pharmaceuticals. To contact Genoa Pharmaceuticals, visit genoapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genoa Pharmaceuticals compare?

A PDF of Genoa Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genoa Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Genoa Pharmaceuticals

Genoa Pharmaceuticals is a biopharmaceutical company that has been at the forefront of developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) since 2011. The company's slogan, "Pioneering a breath of hope with innovative therapies for idiopathic pulmonary fibrosis since 2011," reflects its commitment to innovation in the biopharma and biotechnology industries. In May 15, 2017, Genoa Pharmaceuticals successfully secured a significant $62.00M Series A investment from a consortium of prominent investors including Novo Holdings, F-Prime Capital, RiverVest, Andera Partner, and TPG Biotech. This latest round of funding not only signifies a strong show of confidence in Genoa Pharmaceuticals' approach and potential but also provides the necessary financial support to advance their pioneering work in addressing the substantial unmet medical needs in the field of pulmonary fibrosis. As Genoa Pharmaceuticals continues to make strides in its mission, the recent investment serves as a testament to the company's vision and capabilities. With this substantial backing, Genoa Pharmaceuticals is well-positioned to further its impact and realize its potential in the realm of biopharmaceutical innovation.

Business keywords: Biopharmaceutical, Therapeutics, Idiopathic Pulmonary Fibrosis, GP-101, Pirfenidone, Aerosol Formulation, Inhalation Delivery, IPF Treatment, Biotech Startup, Medical Innovation, San Diego, California, Pioneering Therapies, Respiratory Diseases, Clinical Development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $62.00M 5
Novo Holdings F-Prime Capital RiverVest
Novo Holdings, F-Prime Capital +3
15 May 2017
Seed Round $2.18M -
13 Aug 2015

Genoa Pharmaceuticals Alternatives & Competitors

View All Alternatives
Genoa Pharmaceuticals vs
Kither Biotech
Kither Biotech Italy

Improving treatment for patients suffering from incurable respiratory diseases

Series B
18 employees
Biopharma, Biotechnology
Genoa Pharmaceuticals vs
Avalyn Pharma
Avalyn Pharma United States

Revolutionizing respiratory care with every breath

Series C
58 employees
Biopharma, Biotechnology
Compare Genoa Pharmaceuticals vs Avalyn Pharma
Genoa Pharmaceuticals vs
Vicore Pharma AB
Vicore Pharma AB Sweden

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class...

Post-IPO Equity
41 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Genoa Pharmaceuticals

Pioneering a breath of hope with innovative therapies for idiopathic pulmonary fibrosis since 2011.
Genoa Pharmaceuticals was founded in 2011.
Genoa Pharmaceuticals operates in Biopharma and Biotechnology. Its work centres on Biopharmaceutical, Therapeutics, Idiopathic Pulmonary Fibrosis and GP-101.
Genoa Pharmaceuticals has approximately 1 employees.
Genoa Pharmaceuticals has completed 2 funding rounds, raising a total of $64.18M. The latest funding stage is Series A.
Top alternatives and competitors to Genoa Pharmaceuticals include Kither Biotech, Avalyn Pharma, Vicore Pharma AB, RIGImmune Inc., Antharis Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genoa Pharmaceuticals and Kither Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genoa Pharmaceuticals, https://bouncewatch.com/company/genoa-pharmaceuticals, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes